According to Biocom’s 2019 Economic Impact Report Databook, California is now home to three biotech and pharmaceutical hubs, located in the Bay Area (San Francisco), San Diego, and now Los Angeles. With this in mind, analysis can be completed in the Clinical Trials Database of GlobalData’s Pharma Intelligence Center to find more information and trends for the state of California.

Biopharma clusters

Looking at clinical trial sites in California, it can be seen that the three cities mentioned above are the top three cities for the clinical trial sites (Figure 1). Los Angeles had the most clinical trial sites in California with 11%, followed by San Francisco (6.4%) and San Diego (6.3%). Sacramento and Long Beach rounded out the top five.

Figure 2 shows the trends of clinical trials in California by city. Again, Los Angeles was the top city with 15.2% of all clinical trials in the state of California, San Francisco was second with 8.4% trials, and San Diego was third with 6.8% trials. Sacramento was again fourth with now Stanford rounding out the top five.

As for organisations in the state of California, the Stanford University School of Medicine has the most clinical trials with 2.6% of all clinical trials in the state of California. The University of California San Francisco followed with 2.4% while Kaiser Permanente, USC Norris Comprehensive Cancer Center, and Cedars-Sinai Medical Center all had under 2.0%. This can be seen in Figure 3.